About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

Good morning. What happens to an organization after it achieves a moonshot? That has been Albert Bourla’s reality, post-COVID. As the CEO of Pfizer, a company he first joined in 1993, Bourla—a ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. The company purchased Metsera in November for up to $10 billion to reignite its ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer's radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...

Pfizer’s CEO, Albert Bourla, Ph.D., has yet to top the $33 million in compensation that he earned on the coattails of megablockbuster COVID-19 sales in 2022, but a $27.6 million pay package after a ...

We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked about. Pharma giant Pfizer Inc. (NYSE:PFE)’s shares are down by 4.7% over the ...

Pfizer's Chief Talent Officer explains how the "pilot in command" framework scaled from nine teams to 700, and why Workday made it real.

Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad, in response to a question about the drugmaker's ...